Momenta Pharmaceuticals Inc. announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015. Momenta also announced that Bennett M. Shapiro, M.D., will no longer serve as a member of Momenta's Board of Directors following completion of his term ending on June 22, 2016. Dr. Shapiro was a member of the Board of Directors since 2003, serving on the science, compensation, and nominating and corporate governance committees. Dr. Gilman currently serves as the Executive Chairman and interim CEO of ContraFect Corporation and as a member of the board of directors of Vericel, SCYNEXIS and Keryx. He also serves as a member of the board of directors of the Northeastern University Drug Discovery Advisory Board, the Massachusetts Biotechnology Association and the Penn State University Biotechnology Advisory Board.